No abstract

No abstract

(1L) therapy and thirteen trials (n¼ 3,631) reported on treatment as second-line or beyond (>2L). Using 1% cut point, PD-L1 positivity was associated with higher ORR in 1L and >2L and 1yr PFS in >2L. Using a high cut point of 50%, PD-L1 positivity was associated with higher ORR in 1L and >2L, and higher PFS in 1L. Comparison of increasing cut points of PD-L1 expression and outcomes showed a positive correlation with 1yr PFS in 1L, a modest correlation with 1yr PFS in >2L and ORR in 1L and >2L, and little correlation with 1yr OS in 1L and >2L. Sensitivity analysis revealed no difference when excluding studies using the SP142 assay with weaker tumor staining. Conclusion: Within the limitations of current data, there is a positive correlation between increasing cut points of PD-L1 expression and ORR and 1yr PFS, but little correlation with 1yr OS in treatment naive and pretreated patients.

More studies to evaluate the correlation of these with response from immunotherapy agents are warranted. Immunotherapy specific response data, survival, and predictive biomarkers of response will be reported in a future analysis. This study highlighted the importance to test for both of these markers in order to identify a patient subset that may benefit from immunotherapy. Legal entity responsible for the study: Shayma M. Kazmi Funding: None Disclosure: S.M. Kazmi: Speaker for Merck and Eisai. 36P Expression pattern of immune checkpoints programmed death (PD-1) and programmed death-ligand (PD-L1) in retinoblastoma and its prognostic significance

No abstract